论文部分内容阅读
[目的]探讨AIB1在乳腺癌组织中的表达及其与乳腺癌内分泌治疗耐药及预后的关系。[方法]采用免疫组织化学方法检测120例乳腺癌组织、20例癌旁正常乳腺组织、40例良性乳腺病变组织中AIB1表达情况,并分析乳腺癌AIB1表达与乳腺癌内分泌治疗耐药及预后的关系。[结果]乳腺癌组织中AIB1过表达率(40.00%)显著高于正常乳腺组织(10.00%)和乳腺良性病变组织(15.00%)(P<0.05)。内分泌治疗耐药进展病例AIB1蛋白的阳性表达率明显高于内分泌治疗有效病例(60.00%vs27.00%,P<0.05)。[结论]AIB1高表达与乳腺癌内分泌治疗耐药密切相关,AIB1可以作为独立预测乳腺癌内分泌治疗疗效及预后的一个重要参数。
[Objective] To investigate the expression of AIB1 in breast cancer and its relationship with drug resistance and prognosis of breast cancer endocrine therapy. [Method] Immunohistochemistry was used to detect the expression of AIB1 in 120 cases of breast cancer tissues, 20 cases of adjacent normal breast tissues and 40 cases of benign breast lesions. The expression of AIB1 in breast cancer tissues was compared with that in breast cancer patients with endocrine therapy and prognosis relationship. [Results] The overexpression rate of AIB1 (40.00%) in breast cancer tissues was significantly higher than that in normal breast tissues (10.00%) and benign breast lesions tissues (15.00%) (P <0.05). The positive expression rate of AIB1 protein in patients with drug-resistant endocrine therapy was significantly higher than that in endocrine therapy (60.00% vs27.00%, P <0.05). [Conclusion] The high expression of AIB1 is closely related to the endocrine resistance in breast cancer. AIB1 may serve as an independent parameter for predicting the efficacy and prognosis of endocrine therapy in breast cancer.